ECG Software & EKG Management @ CardioComm Solutions, Inc. - Arrhythmia EKG Management, 12 Lead ECG Management, ECG Software, Web Based ECG, EKG software
CardioComm Solutions, Inc

CardioComm Press Releases
News & Media


CardioComm Solutions to Initiate Sales of the HeartCheck™ ECG PEN Device in 602 Shoppers Drug Mart Pharmacies Across Canada

TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE:EKG) (“CardioComm Solutions” or the “Company”) today announced that it has entered into an agreement with Shoppers Drug Mart Inc. (“Shoppers Drug Mart”) for the over-the-counter (“OTC”) sale of the HeartCheck™ ECG PEN device in pharmacies across Canada. The HeartCheck™ ECG PEN has passed regulatory reviews by both Health Canada and the US Food and Drug Administration as the only OTC ECG displaying device personal heart-health monitoring solution available without a physician’s prescription.

The HeartCheck™ PEN will be made available in approximately 602 Shoppers Drug Mart Pharmacies by February 2015 which will coincide with the start of Heart Month. The product will be placed within the diabetes and high blood pressure monitoring devices section of the store planogram.

The HeartCheck™ PEN ECG can store 20 ECG recordings in memory which can be transferred to a computer for review and management. Consumers purchasing the device will have access to the Company’s free GEMS™ Home software and a free first ECG interpretation through the CardioComm Solutions’ SMART Monitoring ECG service. Sales will target those consumers, and their family, who are interested in the preservation of their heart health as well as those at risk for developing arrhythmias due to underlying conditions, especially prior heart attack, prior cardiac surgery, high blood pressure, high cholesterol, heart failure, diabetes and those taking medications that cause arrhythmias.

CardioComm Solutions has been working with pharmacy banner groups to expand introduction of ECG self-screening and monitoring into the consumer market. The HeartCheck™ PEN is as a groundbreaking and proven medical device that meets the pharmacies’ objective of enhancing personalized heart-health monitoring and betterment of their customers’ health.

More information regarding the HeartCheck™ products and SMART monitoring solutions is available at the Company’s web site

download pdf

About CardioComm Solutions
CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms (ECGs) for diagnosis and management of cardiac patients.  Products are sold worldwide through a combination of an external distribution network and a North American-based sales team.  The Company has earned the ISO 13485 certification, is HPB approved, HIPAA compliant, and has received FDA market clearance for its software devices.  CardioComm Solutions is headquartered in Toronto, Canada, with offices in Victoria, B.C.  


Etienne Grima, Chief Executive Officer

Forward-looking statements

This release may contain certain forward-looking statements and forward looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.

In evaluating these statements, readers should: specifically consider risks discussed under the heading "Risk Factors" in the Company's Annual Information Form, available at; not to place undue reliance on forward-looking statements and forward-looking information; be aware. the Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this Annual Information Form other than as required by applicable laws (including without limitation Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations).

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Investor Information
GE Healthcare Notice to MARS® Event Customers

Arrhythmia EKG Management | 12 Lead ECG Management | ECG Software | EKG Management | Web Based ECG | EKG Software